Publicação
Endocan as a marker of endotheliitis in COVID-19 patients
| Resumo: | BACKGROUND AND AIMS: Endocan has been scarcely explored in COVID-19, especially regarding its modulation by veno-venous extracorporeal membrane oxygenation (VV-ECMO), hypertension or previous renin-angiotensin-aldosterone system (RAAS) inhibitors treatment. We compared endocan and other endotheliitis markers in hospitalized COVID-19 patients and assessed their modulation by VV-ECMO, hypertension and previous RAAS inhibitors treatment. MATERIAL AND METHODS: Serum endocan, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin were measured in "severe" (n = 27), "critically ill" (n = 17) and "critically ill on VV-ECMO" (n = 17) COVID-19 patients at admission, days 3-4, 5-8 and weekly thereafter, and in controls (n = 23) at a single time point. RESULTS: Admission endocan and VCAM-1 were increased in all patients, but "critically ill on VV-ECMO" patients had higher endocan and E-Selectin. Endocan remained elevated throughout hospitalization in all groups. "Severe" and "critically ill" hypertensive patients or previously treated with RAAS inhibitors had higher endocan and/or VCAM-1, but in VV-ECMO patients the raised endocan values seemed unrelated with these factors. Among all COVID-19 hypertensive patients, those with previous RAAS inhibitors treatment had higher endocan. CONCLUSIONS: In our study, endocan stands out as the best marker of endotheliitis in hospitalized COVID-19 patients, being upregulated by VV-ECMO support, hypertension and previous RAAS inhibitor treatment. |
|---|---|
| Autores principais: | Reina-Couto, Marta |
| Outros Autores: | Alves, David; Silva-Pereira, Carolina; Pereira-Terra, Patrícia; Martins, Sandra; Bessa, João; Teixeira-Santos, Luísa; Pinho, Dora; Morato, Manuela; Dias, Cláudia Camila; Sarmento, António; Tavares, Margarida; Guimarães, João T.; Roncon-Albuquerque, Roberto; Paiva, José Artur; Albino-Teixeira, António; Sousa, Teresa |
| Assunto: | COVID-19 Endocan Endotheliitis Hypertension RAAS inhibitors VV-ECMO Immunology Pharmacology |
| Ano: | 2025 |
| País: | Portugal |
| Tipo de documento: | artigo |
| Tipo de acesso: | acesso aberto |
| Instituição associada: | Universidade Nova de Lisboa |
| Idioma: | inglês |
| Origem: | Repositório Institucional da UNL |
| _version_ | 1868983570040619008 |
|---|---|
| author | Reina-Couto, Marta |
| author2 | Alves, David Silva-Pereira, Carolina Pereira-Terra, Patrícia Martins, Sandra Bessa, João Teixeira-Santos, Luísa Pinho, Dora Morato, Manuela Dias, Cláudia Camila Sarmento, António Tavares, Margarida Guimarães, João T. Roncon-Albuquerque, Roberto Paiva, José Artur Albino-Teixeira, António Sousa, Teresa |
| author2_role | author author author author author author author author author author author author author author author author |
| author_facet | Reina-Couto, Marta Alves, David Silva-Pereira, Carolina Pereira-Terra, Patrícia Martins, Sandra Bessa, João Teixeira-Santos, Luísa Pinho, Dora Morato, Manuela Dias, Cláudia Camila Sarmento, António Tavares, Margarida Guimarães, João T. Roncon-Albuquerque, Roberto Paiva, José Artur Albino-Teixeira, António Sousa, Teresa |
| author_role | author |
| contributor_name_str_mv | NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) Springer Science and Business Media Deutschland GmbH RUN |
| country_str | PT |
| creators_json_txt | [{\"Person.name\":\"Reina-Couto, Marta\"},{\"Person.name\":\"Alves, David\"},{\"Person.name\":\"Silva-Pereira, Carolina\"},{\"Person.name\":\"Pereira-Terra, Patrícia\"},{\"Person.name\":\"Martins, Sandra\"},{\"Person.name\":\"Bessa, João\"},{\"Person.name\":\"Teixeira-Santos, Luísa\"},{\"Person.name\":\"Pinho, Dora\"},{\"Person.name\":\"Morato, Manuela\"},{\"Person.name\":\"Dias, Cláudia Camila\"},{\"Person.name\":\"Sarmento, António\"},{\"Person.name\":\"Tavares, Margarida\"},{\"Person.name\":\"Guimarães, João T.\"},{\"Person.name\":\"Roncon-Albuquerque, Roberto\"},{\"Person.name\":\"Paiva, José Artur\"},{\"Person.name\":\"Albino-Teixeira, António\"},{\"Person.name\":\"Sousa, Teresa\"}] |
| datacite.contributors.contributor.contributorName.fl_str_mv | NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) Springer Science and Business Media Deutschland GmbH RUN |
| datacite.creators.creator.creatorName.fl_str_mv | Reina-Couto, Marta Alves, David Silva-Pereira, Carolina Pereira-Terra, Patrícia Martins, Sandra Bessa, João Teixeira-Santos, Luísa Pinho, Dora Morato, Manuela Dias, Cláudia Camila Sarmento, António Tavares, Margarida Guimarães, João T. Roncon-Albuquerque, Roberto Paiva, José Artur Albino-Teixeira, António Sousa, Teresa |
| datacite.date.Accepted.fl_str_mv | 2025-01-25T00:00:00Z |
| datacite.date.available.fl_str_mv | 2025-02-18T21:21:07Z |
| datacite.date.embargoed.fl_str_mv | 2025-02-18T21:21:07Z |
| datacite.rights.fl_str_mv | http://purl.org/coar/access_right/c_abf2 |
| datacite.subjects.subject.fl_str_mv | COVID-19 Endocan Endotheliitis Hypertension RAAS inhibitors VV-ECMO Immunology Pharmacology |
| datacite.titles.title.fl_str_mv | Endocan as a marker of endotheliitis in COVID-19 patients modulation by veno-venous extracorporeal membrane oxygenation, arterial hypertension and previous treatment with renin-angiotensin-aldosterone system inhibitors |
| dc.contributor.none.fl_str_mv | NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) Springer Science and Business Media Deutschland GmbH RUN |
| dc.creator.none.fl_str_mv | Reina-Couto, Marta Alves, David Silva-Pereira, Carolina Pereira-Terra, Patrícia Martins, Sandra Bessa, João Teixeira-Santos, Luísa Pinho, Dora Morato, Manuela Dias, Cláudia Camila Sarmento, António Tavares, Margarida Guimarães, João T. Roncon-Albuquerque, Roberto Paiva, José Artur Albino-Teixeira, António Sousa, Teresa |
| dc.date.Accepted.fl_str_mv | 2025-01-25T00:00:00Z |
| dc.date.available.fl_str_mv | 2025-02-18T21:21:07Z |
| dc.date.embargoed.fl_str_mv | 2025-02-18T21:21:07Z |
| dc.format.none.fl_str_mv | application/pdf |
| dc.identifier.none.fl_str_mv | http://hdl.handle.net/10362/179283 |
| dc.language.none.fl_str_mv | eng |
| dc.rights.none.fl_str_mv | http://purl.org/coar/access_right/c_abf2 |
| dc.subject.none.fl_str_mv | COVID-19 Endocan Endotheliitis Hypertension RAAS inhibitors VV-ECMO Immunology Pharmacology |
| dc.title.fl_str_mv | Endocan as a marker of endotheliitis in COVID-19 patients modulation by veno-venous extracorporeal membrane oxygenation, arterial hypertension and previous treatment with renin-angiotensin-aldosterone system inhibitors |
| dc.type.none.fl_str_mv | http://purl.org/coar/resource_type/c_6501 |
| description | BACKGROUND AND AIMS: Endocan has been scarcely explored in COVID-19, especially regarding its modulation by veno-venous extracorporeal membrane oxygenation (VV-ECMO), hypertension or previous renin-angiotensin-aldosterone system (RAAS) inhibitors treatment. We compared endocan and other endotheliitis markers in hospitalized COVID-19 patients and assessed their modulation by VV-ECMO, hypertension and previous RAAS inhibitors treatment. MATERIAL AND METHODS: Serum endocan, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin were measured in "severe" (n = 27), "critically ill" (n = 17) and "critically ill on VV-ECMO" (n = 17) COVID-19 patients at admission, days 3-4, 5-8 and weekly thereafter, and in controls (n = 23) at a single time point. RESULTS: Admission endocan and VCAM-1 were increased in all patients, but "critically ill on VV-ECMO" patients had higher endocan and E-Selectin. Endocan remained elevated throughout hospitalization in all groups. "Severe" and "critically ill" hypertensive patients or previously treated with RAAS inhibitors had higher endocan and/or VCAM-1, but in VV-ECMO patients the raised endocan values seemed unrelated with these factors. Among all COVID-19 hypertensive patients, those with previous RAAS inhibitors treatment had higher endocan. CONCLUSIONS: In our study, endocan stands out as the best marker of endotheliitis in hospitalized COVID-19 patients, being upregulated by VV-ECMO support, hypertension and previous RAAS inhibitor treatment. |
| dirty | 0 |
| eu_rights_str_mv | openAccess |
| format | article |
| fulltext.url.fl_str_mv | https://run.unl.pt/bitstreams/64e20dfb-daff-4c3a-a15c-46e1b80a6a54/download |
| id | run_659e010f124a5881908e8a75a7367656 |
| identifier.url.fl_str_mv | http://hdl.handle.net/10362/179283 |
| inst_facet_str | urn:organizationAcronym:unl{{{_:::_}}}Universidade Nova de Lisboa |
| instacron_str | unl |
| institution | Universidade Nova de Lisboa |
| instname_str | Universidade Nova de Lisboa |
| language | eng |
| network_acronym_str | run |
| network_name_str | Repositório Institucional da UNL |
| oai_identifier_str | oai:run.unl.pt:10362/179283 |
| organization_str_mv | urn:organizationAcronym:unl |
| person_str_mv | Reina-Couto, Marta Alves, David Silva-Pereira, Carolina Pereira-Terra, Patrícia Martins, Sandra Bessa, João Teixeira-Santos, Luísa Pinho, Dora Morato, Manuela Dias, Cláudia Camila Sarmento, António Tavares, Margarida Guimarães, João T. Roncon-Albuquerque, Roberto Paiva, José Artur Albino-Teixeira, António Sousa, Teresa |
| publishDate | 2025 |
| repo_facet_str | urn:repositoryAcronym:run{{{_:::_}}}Repositório Institucional da UNL |
| reponame_str | Repositório Institucional da UNL |
| repository_id_str | urn:repositoryAcronym:run |
| service_str_mv | urn:repositoryAcronym:run |
| spelling | engenBACKGROUND AND AIMS: Endocan has been scarcely explored in COVID-19, especially regarding its modulation by veno-venous extracorporeal membrane oxygenation (VV-ECMO), hypertension or previous renin-angiotensin-aldosterone system (RAAS) inhibitors treatment. We compared endocan and other endotheliitis markers in hospitalized COVID-19 patients and assessed their modulation by VV-ECMO, hypertension and previous RAAS inhibitors treatment. MATERIAL AND METHODS: Serum endocan, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin were measured in "severe" (n = 27), "critically ill" (n = 17) and "critically ill on VV-ECMO" (n = 17) COVID-19 patients at admission, days 3-4, 5-8 and weekly thereafter, and in controls (n = 23) at a single time point. RESULTS: Admission endocan and VCAM-1 were increased in all patients, but "critically ill on VV-ECMO" patients had higher endocan and E-Selectin. Endocan remained elevated throughout hospitalization in all groups. "Severe" and "critically ill" hypertensive patients or previously treated with RAAS inhibitors had higher endocan and/or VCAM-1, but in VV-ECMO patients the raised endocan values seemed unrelated with these factors. Among all COVID-19 hypertensive patients, those with previous RAAS inhibitors treatment had higher endocan. CONCLUSIONS: In our study, endocan stands out as the best marker of endotheliitis in hospitalized COVID-19 patients, being upregulated by VV-ECMO support, hypertension and previous RAAS inhibitor treatment.application/pdfenEndocan as a marker of endotheliitis in COVID-19 patientsSubtitleenmodulation by veno-venous extracorporeal membrane oxygenation, arterial hypertension and previous treatment with renin-angiotensin-aldosterone system inhibitorsReina-Couto, MartaAlves, DavidSilva-Pereira, CarolinaPereira-Terra, PatríciaMartins, SandraBessa, JoãoTeixeira-Santos, LuísaPinho, DoraMorato, ManuelaDias, Cláudia CamilaSarmento, AntónioTavares, MargaridaGuimarães, João T.Roncon-Albuquerque, RobertoPaiva, José ArturAlbino-Teixeira, AntónioSousa, TeresaNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)Springer Science and Business Media Deutschland GmbHHostingInstitutionOrganizationalRUNe-mailmailto:run@unl.ptrun@unl.ptISSNIsPartOf1420-908XURNIsPartOfPURE: 109998935URNIsPartOfPURE UUID: f0e3247f-4110-4de0-823a-8cc6cfdc60faURNIsPartOfScopus: 85217001794URNIsPartOfPubMed: 39862311DOIIsPartOf10.1007/s00011-024-01964-82025-02-18T21:21:07Z2025-01-252025-01-25T00:00:00ZHandlehttp://hdl.handle.net/10362/179283http://purl.org/coar/access_right/c_abf2open accessCOVID-19EndocanEndotheliitisHypertensionRAAS inhibitorsVV-ECMOImmunologyPharmacology2908623 bytesliteraturehttp://purl.org/coar/resource_type/c_6501journal articlehttp://purl.org/coar/access_right/c_abf2application/pdffulltexthttps://run.unl.pt/bitstreams/64e20dfb-daff-4c3a-a15c-46e1b80a6a54/download |
| spellingShingle | Endocan as a marker of endotheliitis in COVID-19 patients Reina-Couto, Marta COVID-19 Endocan Endotheliitis Hypertension RAAS inhibitors VV-ECMO Immunology Pharmacology |
| status | SINGLETON |
| subject.fl_str_mv | COVID-19 Endocan Endotheliitis Hypertension RAAS inhibitors VV-ECMO Immunology Pharmacology |
| title | Endocan as a marker of endotheliitis in COVID-19 patients |
| title_full | Endocan as a marker of endotheliitis in COVID-19 patients |
| title_fullStr | Endocan as a marker of endotheliitis in COVID-19 patients |
| title_full_unstemmed | Endocan as a marker of endotheliitis in COVID-19 patients |
| title_short | Endocan as a marker of endotheliitis in COVID-19 patients |
| title_sort | Endocan as a marker of endotheliitis in COVID-19 patients |
| topic | COVID-19 Endocan Endotheliitis Hypertension RAAS inhibitors VV-ECMO Immunology Pharmacology |
| topic_facet | COVID-19 Endocan Endotheliitis Hypertension RAAS inhibitors VV-ECMO Immunology Pharmacology |
| url | http://hdl.handle.net/10362/179283 |
| visible | 1 |